title: Catastrophic eruptive keratoacanthomas and squamous cell cancers after treatment with an FLT3 inhibitor quizartinib (AC220).
authors.affiliation: Department of Dermatology, University of Wisconsin-Madison Hospital and Clinics, Madison, Wisconsin Department of Dermatology, University of Wisconsin-Madison Hospital and Clinics, Madison, Wisconsin Madison Skin & Research Inc., Madison, Wisconsin.
authors.forename: Kirstin
authors.initials: K
authors.lastname: Altman
authors.forename: Harry
authors.initials: H
authors.lastname: Sharata
mesh_terms: D000368:Aged; D052160:Benzothiazoles / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D005500:Follow-Up Studies; D006801:Humans; D007636:Keratoacanthoma / Q000139:chemically induced* / Q000175:diagnosis; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D018307:Neoplasms, Squamous Cell / Q000139:chemically induced* / Q000175:diagnosis; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D052160:Benzothiazoles; D010671:Phenylurea Compounds; C544967:quizartinib; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3